AusMed Innovations Drug Test - 14 Panel Urine Cup

Comprehensive 14-panel urine drug screening

Screens for AMP, BZO, BUP, COC, THC, MTD, MET, MOP/OPI, KET, OXY, FYL, PGB, GAB and QTP

Includes screening for Pregabalin, Gabapentin and Quetiapine

Rapid chromatographic immunoassay

No instrument or reader required

Visual test results

Built-in procedural control

Convenient urine collection cup format

Individually sealed for use

Suitable for professional point-of-collection screening

Intended for in vitro diagnostic use

Designed for use in accordance with AS/NZS 4308:2023

Creatinine specimen-integrity check not included

Product: AusMed Innovations Multi-Drug Rapid Test Cup
Configuration: 14-panel
Specimen: Human urine
Test Type: Rapid chromatographic immunoassay
Creatinine Check: No
Result Type: Qualitative preliminary screening
Storage: 2–30°C
Freezing: Do not freeze
Intended Use: In vitro diagnostic use by healthcare professionals and appropriately trained drug-testing personnel

Drug Panels & Cut-Offs

• Amphetamine (AMP): 300 ng/mL
• Benzodiazepines (BZO): 200 ng/mL
• Buprenorphine (BUP): 10 ng/mL
• Cocaine (COC): 150 ng/mL
• Fentanyl (FYL): 10 ng/mL
• Marijuana/Cannabis (THC): 50 ng/mL
• Methadone (MTD): 300 ng/mL
• Methamphetamine (MET): 300 ng/mL
• Morphine/Opiates (MOP/OPI): 300 ng/mL
• Ketamine (KET): 100 ng/mL
• Oxycodone (OXY): 100 ng/mL
• Pregabalin (PGB): 500 ng/mL
• Gabapentin (GAB): 2,000 ng/mL
• Quetiapine (QTP): 1,000 ng/mL

The AusMed Innovations 14 Panel Multi-Drug Rapid Test Cup provides a qualitative preliminary screening result only. Non-negative results should be confirmed using an appropriate laboratory analytical method such as LC-MS/MS or GC-MS, with confirmation performed by a NATA-accredited laboratory where applicable.

Unlike the 6-panel and 11-panel configurations, this 14-panel cup does not include a creatinine specimen-integrity check, as the expanded panel configuration does not have sufficient space for the additional check.

A non-negative screening result does not indicate a level of intoxication or impairment. A negative result indicates that the concentration is below the applicable screening cut-off and does not necessarily mean that the drug or metabolite is completely absent.

Testing should be performed by appropriately trained personnel and in accordance with applicable procedures and AS/NZS 4308:2023.